|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Top Lists |
Insider Trading Graph View |
Insider Watch |
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise" - Peter Lynch ==>> What is insider trading>> |

| Transaction & Date | Reported Date |
Company | Symbol | Insider Relationship |
Shares Traded | Average Price | Total Amount |
Shares Ownership |
Filing |
| 2008-04-15 Purchase |
2009-07-20 4:35 pm | Nile Therapeutics, Inc. | NLTX | Lieu Hsiao (VP, Clinical Research) | 100 | $4.6 | $460 | 100 (Direct) | View |
| 2009-07-07 Purchase | 2009-07-09 5:48 pm |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 3,952 | $0 | $0 | 14,152 (Direct) |
View |
| 2009-07-07 Purchase | 2009-07-09 5:46 pm | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 98,814 | $0 | $0 | 1,596,208 (Direct) | View |
| 2009-07-07 Purchase |
2009-07-09 5:42 pm |
Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 197,628 | $0 | $0 | 1,278,228 (Direct) | View |
| 2009-03-12 Purchase | 2009-03-13 7:45 pm |
Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 510 | $0.75 | $382 | 1,080,600 (Direct) |
View |
| 2009-03-11- -2009-03-13 Purchase |
2009-03-13 7:35 pm | Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 11,000 | $0.7609 | $8,370 | 9,200 (Direct Indirect) |
View |
| 2008-12-16 Purchase |
2008-12-16 9:29 pm | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 3,100 | $1.15 | $3,565 | 1,080,090 (Direct) | View |
| 2008-12-16 Purchase | 2008-12-16 9:19 pm | Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 2,500 | $1.15 | $2,875 | 1,520,705 (Direct) |
View |
| 2008-12-15 Purchase | 2008-12-15 8:51 pm | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 2,500 | $1.05 | $2,625 | 1,076,990 (Direct) |
View |
| 2008-12-12- -2008-12-15 Purchase | 2008-12-15 8:41 pm | Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 6,500 | $1.307 | $8,495 | 1,518,205 (Direct) | View |
| 2008-12-12 Purchase | 2008-12-12 7:42 pm |
Nile Therapeutics, Inc. | NLTX | Strumph Peter M (Chief Executive Officer Director) | 3,000 | $0.86 | $2,580 | 7,580 (Direct) |
View |
| 2008-12-12 Purchase |
2008-12-12 7:29 pm |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 4,186 | $0.8314 | $3,480 | 4,200 (Direct Indirect) |
View |
| 2008-12-11- -2008-12-12 Purchase | 2008-12-12 7:27 pm |
Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 4,600 | $1.192 | $5,483 | 1,496,344 (Direct) | View |
| 2008-12-11- -2008-12-12 Purchase |
2008-12-12 7:25 pm | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 8,200 | $1.132 | $9,284 | 1,074,490 (Direct) |
View |
| 2008-12-11 Purchase |
2008-12-12 06:04 am | Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 3,814 | $0.7524 | $2,870 | 1,014 (Direct Indirect) |
View |
| 2008-12-11 Purchase | 2008-12-12 06:03 am | Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 4,000 | $0.6918 | $2,767 | 1,511,705 (Direct) | View |
| 2008-12-11 Purchase | 2008-12-12 06:02 am |
Nile Therapeutics, Inc. | NLTX | Strumph Peter M (Chief Executive Officer Director) | 3,580 | $0.6028 | $2,158 | 4,580 (Direct) | View |
| 2008-04-15 Purchase |
2008-04-16 5:52 pm |
Nile Therapeutics, Inc. | NILT.OB | SCHAFER GREGORY W (Director) | 100 | $4.6 | $460 | 100 (Direct) |
View |
| 2008-04-14 Purchase |
2008-04-16 5:28 pm |
Nile Therapeutics, Inc. | NILT.OB | Evans Daron (Chief Financial Officer) | 800 | $4.55 | $3,640 | 200 (Direct Indirect) |
View |
| Transaction & Date | Reported Date | Exercisable Expiration | Company | Symbol | Insider Relationship |
Shares Traded | Conversion Price | Shares Ownership |
Filing |
| 2009-09-24 Option Award |
2009-09-28 9:07 pm | N/A 2019-09-24 |
Nile Therapeutics, Inc. | NLTX | Belldegrun Arie (Director) | 130,000 | $1.46 | 130,000 (Direct) |
View |
| 2009-09-24 Option Award | 2009-09-28 9:04 pm |
N/A 2019-09-24 | Nile Therapeutics, Inc. | NLTX | Litvack Frank (Director) | 130,000 | $1.46 | 130,000 (Direct) | View |
| 2009-01-16 Option Award |
2009-08-21 3:50 pm | 2009-01-16 2019-01-15 | Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 49,020 | $0.88 | 49,020 (Direct) | View |
| 2009-01-16 Option Award | 2009-08-21 3:50 pm |
N/A 2017-09-17 |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 43,269 | $2.71 | 43,269 (Direct) | View |
| 2009-07-21 Option Award | 2009-07-23 5:37 pm | 2010-07-21 2019-07-21 |
Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 65,000 | $1.77 | 65,000 (Direct) |
View |
| 2009-07-21 Option Award | 2009-07-23 5:34 pm | 2010-07-21 2019-07-21 | Nile Therapeutics, Inc. | NLTX | SCHAFER GREGORY W (Director) | 80,000 | $1.77 | 80,000 (Direct) |
View |
| 2009-07-21 Option Award |
2009-07-23 5:33 pm |
2010-07-21 2019-07-21 | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Chief Executive Officer Director) | 65,000 | $1.77 | 65,000 (Direct) |
View |
| 2009-07-21 Option Award | 2009-07-23 5:31 pm |
2010-07-21 2019-07-21 |
Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 80,000 | $1.77 | 80,000 (Direct) | View |
| 2009-07-21 Option Award | 2009-07-23 5:29 pm | 2010-07-21 2019-07-21 | Nile Therapeutics, Inc. | NLTX | GRANADILLO PEDRO P (Director) | 80,000 | $1.77 | 80,000 (Direct) | View |
| 2009-07-21 Option Award | 2009-07-23 3:48 pm |
2010-07-21 2019-07-21 | Nile Therapeutics, Inc. | NLTX | Mieyal Paul A (Director) | 65,000 | $1.77 | 65,000 (Direct) | View |
| 2008-03-10 Option Award |
2009-07-20 4:35 pm | N/A 2018-03-10 |
Nile Therapeutics, Inc. | NLTX | Lieu Hsiao (VP, Clinical Research) | 200,000 | $4.45 | 200,000 (Direct) |
View |
| 2009-01-16 Option Award | 2009-07-20 4:35 pm |
2009-01-16 2019-01-16 |
Nile Therapeutics, Inc. | NLTX | Lieu Hsiao (VP, Clinical Research) | 9,123 | $4.45 | 9,123 (Direct) | View |
| 2009-01-16 Option Award | 2009-07-20 4:35 pm | 2009-01-16 2019-01-16 | Nile Therapeutics, Inc. | NLTX | Lieu Hsiao (VP, Clinical Research) | 31,003 | $0.88 | 31,003 (Direct) | View |
| 2009-07-07 Option Award | 2009-07-20 4:35 pm | 2009-07-07 2019-07-07 | Nile Therapeutics, Inc. | NLTX | Lieu Hsiao (VP, Clinical Research) | 37,500 | $1.14 | 37,500 (Direct) | View |
| 2009-07-15 Other |
2009-07-16 5:15 pm | 2009-07-15 2019-07-15 | Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 31,650 | $1.375 | 31,650 (Direct) | View |
| 2009-07-15 Other |
2009-07-16 5:11 pm | 2009-07-15 2019-07-15 | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 31,650 | $1.375 | 31,650 (Direct) |
View |
| 2009-07-15 Other | 2009-07-16 5:05 pm |
2009-07-15 2019-07-15 | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 125,000 | $1.375 | 125,000 (Direct) |
View |
| 2009-07-07 Purchase | 2009-07-09 5:48 pm | 2009-07-07 2014-07-07 |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 988 | $1.25 | 988 (Direct) |
View |
| 2009-07-07 Purchase | 2009-07-09 5:48 pm | 2009-07-07 2014-07-07 |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 988 | $1.71 | 988 (Direct) | View |
| 2009-07-07 Purchase | 2009-07-09 5:48 pm |
2009-07-07 2014-07-07 |
Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 1,976 | $2.28 | 1,976 (Direct) | View |
| 2009-07-07 Purchase |
2009-07-09 5:46 pm | 2009-07-07 2014-07-07 | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 24,704 | $1.25 | 24,704 (Direct) |
View |
| 2009-07-07 Purchase |
2009-07-09 5:46 pm |
2009-07-07 2014-07-07 | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 24,703 | $1.71 | 24,703 (Direct) | View |
| 2009-07-07 Purchase |
2009-07-09 5:46 pm | 2009-07-07 2014-07-07 | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 49,407 | $2.28 | 49,407 (Direct) |
View |
| 2009-07-07 Purchase | 2009-07-09 5:42 pm | 2009-07-07 2014-07-07 | Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 49,407 | $1.25 | 49,407 (Direct) | View |
| 2009-07-07 Purchase |
2009-07-09 5:42 pm | 2009-07-07 2014-07-07 |
Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 49,407 | $1.71 | 49,407 (Direct) | View |
| 2009-07-07 Purchase | 2009-07-09 5:42 pm |
2009-07-07 2014-07-07 |
Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 98,814 | $2.28 | 98,814 (Direct) |
View |
| 2009-06-24 Option Award |
2009-06-26 6:46 pm |
2009-06-24 2019-06-24 | Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 25,000 | $0.89 | 25,000 (Direct) | View |
| 2008-12-23 Option Award |
2009-01-22 1:27 pm |
N/A 2018-12-22 | Nile Therapeutics, Inc. | NTLX | Mieyal Paul A (Director) | 25,000 | $0.93 | 25,000 (Direct) |
View |
| 2009-01-16 Option Award | 2009-01-20 7:19 pm |
N/A 2019-01-15 | Nile Therapeutics, Inc. | NLTX | Evans Daron (Chief Financial Officer) | 49,020 | $0.88 | 49,020 (Direct) |
View |
| 2009-01-16 Option Award |
2009-01-20 7:14 pm | N/A 2019-01-15 |
Nile Therapeutics, Inc. | NLTX | Strumph Peter M (Chief Executive Officer Director) | 149,148 | $0.88 | 149,148 (Direct) |
View |
| 2008-12-23 Option Award | 2008-12-23 9:24 pm |
N/A 2018-12-22 | Nile Therapeutics, Inc. | NLTX | SCHAFER GREGORY W (Director) | 35,000 | $0.93 | 35,000 (Direct) | View |
| 2008-12-23 Option Award | 2008-12-23 9:23 pm | N/A 2018-12-22 |
Nile Therapeutics, Inc. | NLTX | GRANADILLO PEDRO P (Director) | 35,000 | $0.93 | 35,000 (Direct) | View |
| 2008-12-23 Option Award |
2008-12-23 8:57 pm |
N/A 2018-12-22 |
Nile Therapeutics, Inc. | NLTX | TANEN DAVID M (Director) | 25,000 | $0.93 | 25,000 (Direct) | View |
| 2008-12-23 Option Award |
2008-12-23 8:50 pm | N/A 2018-12-22 |
Nile Therapeutics, Inc. | NLTX | Kazam Joshua A (Director) | 25,000 | $0.93 | 25,000 (Direct) |
View |
| 2008-12-23 Option Award | 2008-12-23 8:42 pm | N/A 2018-12-22 | Nile Therapeutics, Inc. | NLTX | KASH PETER M (Director) | 35,000 | $0.93 | 35,000 (Direct) | View |
|
© 2005-2009 SecForm4.Com All rights reserved. Archives: 2009 2008 2007 2006 2005 2004 ... Sat, 21 Nov 2009 15:30:57 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |